Fas and Fas ligand: lpr and gld mutations☆
References (46)
- et al.
Cell
(1991) - et al.
J. Biol. Chem.
(1992) - et al.
Cell
(1993) - et al.
Cell
(1994) - et al.
Biochem. Biophys. Res. Commun.
(1993) Cell
(1994)Cell
(1994)- et al.
Cell
(1990) - et al.
Curr. Opin. Immunol.
(1993) - et al.
Immunol. Today
(1993)
J. Exp. Med.
(1989)
Science
(1989)
J. Immunol.
(1992)
J. Exp. Med.
(1993)
J. Exp. Med.
(1994)
Int. Immunol.
(1994)
J. Exp. Med.
(1978)
Biochem. Genet.
(1991)
J. Exp. Med.
(1984)
Mammalian Genome
(1992)
J. Exp. Med.
(1991)
Annu. Rev. Immunol.
(1991)
Cited by (843)
Immunological Tolerance
2022, Encyclopedia of Infection and ImmunitySoluble CD95L in cancers and chronic inflammatory disorders, a new therapeutic target?
2021, Biochimica et Biophysica Acta - Reviews on CancerMolecular mechanisms of FasL-mediated ‘reverse-signaling’
2020, Molecular ImmunologyCaspase-8: The double-edged sword
2020, Biochimica et Biophysica Acta - Reviews on Cancer
- ☆
We thank O. Hayaishi and C. Weissmann for encouragement and discussion. The work was carried out in collaboration with M. Adachi, J. Ogasawara, T. Takahashi, M. Tanaka, T. Kondo, M. Enari, H. Hug, N. Itoh and R. Watanabe-Fukunaga, and supported in part by Grants-in-Aid from the Ministry of Education, Science and Culture of Japan. We also thank K. Mimura for secretarial assistance.
- 1
Shigekazu Nagata and Takashi Suda are at the Osaka Bioscience Institute, 6-2-4 Furuedai, Suita-shi, Osaka 565, Japan.
Copyright © 1995 Published by Elsevier Ltd.